Bristol-Myers Squibb (France)

Recent papers from Bristol-Myers Squibb (France)

1. Economic Burden of treated Lower-Risk Myelodysplastic Syndromes in France: A Population-Based StudyClinicoEconomics and Outcomes Research · 2026
2. Quality of life and care experience in durable responders to immune checkpoint inhibitors for advanced or metastatic NSCLC or melanomaImmuno-Oncology Technology · 2026
3. Hospitalization at home use analysis for immune checkpoint inhibitors administrations in France: Care pathways, costs and development opportunitiesBulletin du Cancer · 2026
4. Real-World Use of Adjuvant Nivolumab for Resected Stage III–IV Melanoma: 2-Year Analysis of AdjuMelDermatology and Therapy · 2026
5. Model‐informed optimal dose selection of golcadomide in combination with R‐CHOP in patients with previously untreated aggressive B‐cell lymphomaBritish Journal of Clinical Pharmacology · 2026
6. Real-world treatment patterns and clinical outcomes among patients with relapsed/refractory multiple myeloma initiating their second, third, and fourth lines of treatment: data from the US Flatiron databaseLeukemia & lymphoma/Leukemia and lymphoma · 2026
7. Comment on Tekin et al. Novel Conservative Therapies in Migraine Management: The Impact of Fascia Exercises in a Randomized Controlled Trial. J. Clin. Med. 2025, 14, 539Journal of Clinical Medicine · 2026
8. Epidemiology and Treatment Patterns of Stage III Resectable Melanoma Treated with Adjuvant Therapy: A Real-World Study Using the SNDS Database in FranceDermatology and Therapy · 2026
9. Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD, plus rituximab (R) versus investigator’s choice (IC) in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL) who have received ≥ 1 line of systemic therapy: GOLSEEK-4, a phase (Ph) 3, randomized study.Journal of Clinical Oncology · 2026
10. Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD, + Pola-RCHP in patients (pts) with newly diagnosed aggressive B-cell lymphoma (a-BCL): Safety and 12-month (mo) efficacy results.Journal of Clinical Oncology · 2026
11. Untangling the Osteopathic Gordian Knot: Reconceptualized Principles for Sustainable and Contemporary Clinical Practice—A Conceptual PerspectiveHealthcare · 2026
12. Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study.2026
13. Clinical Development of Novel-Novel Multi-Company Combination Therapies in Oncology.2026
14. Unraveling the care pathway for CAR T-cell therapy in large B-cell lymphoma: insights from a nationwide study in France (2018-2023).2026
15. Abstract CT015: Clinical outcomes by genomic markers and ctDNA dynamics with perioperative nivolumab (NIVO) for resectable NSCLC from CheckMate 77TCancer Research · 2026
16. The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trialJNCI Journal of the National Cancer Institute · 2026
17. Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysisBlood · 2026
18. 371P System dynamics analysis of access pathways and hurdles for ctDNA-based MRD testing in solid tumorsESMO Open · 2026
19. Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell LymphomaEuropean Journal Of Haematology · 2026
20. Osteopathic Manipulative Treatment in 564 Children with Congenital Heart Disease: A Project ReportChildren · 2026